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Abstract. Cancer is a leading cause of mortality and the 
majority of deaths are due to metastases. Many molecules 
have been implicated in the development of metastases. 
Signal induced proliferation associated protein 1 (SIPA1), a 
mitogen‑inducible gene, has been demonstrated to be involved 
in the metastasis of various solid tumours and may indicate a 
poor prognosis. Polymorphisms of SIPA1 can be associated 
with several different types of cancer and interactions between 
SIPA1 and binding molecules integrate a series of cellular 
functions, which may promote the development and metastasis 
of cancer. The mechanisms by which SIPA1 promotes the 
development and metastasis of cancer varies among tumour 
types. The present review describes the structure, function 
and regulation of SIPA1 and focuses on its role in cancer 
metastasis. Possibilities for future research and the clinical 
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1. Introduction
Since Dr. Stephen Paget proposed the ‘seed and soil’ theory of 
metastasis in 1889 (1), the mechanism of cancer metastasis has 
been an area of interest (2). Cancer metastasis has been shown 
to be a complex process involving multiple factors including 
sustaining proliferative signalling and evading growth suppres‑
sors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, activating invasion, migration and 
drug resistance (3,4). Increasing numbers of oncogenes, such 
as ErbB2, PI3KCA, MYC, CCND1 and tumour suppressor 
genes,	such	as	p53	and	Rb	have	been	identified	as	being	related	
to tumour metastasis (5). Additionally, many more signalling 
pathways have been found to play an essential role in the 
development and progress of cancer including TGF‑β (6), 
MAPK (7), Wnt (8), NOTCH (9), Fak (10), PI3K/Akt (11,12). 
Among all these oncogenes, signal‑induced proliferation‑asso‑
ciated protein 1 (SIPA1), a mitogen‑inducible gene encoding a 
GTPase‑activating	protein	for	Rap1	and	Rap2,	was	identified	as	
an important moderator participating in several cancer related 
signalling pathways (13). In this paper, we focus on SIPA1 ‑ 
the structures of SIPA1 gene and protein, the relationships 
between polymorphisms of SIPA1 and tumour susceptibility, 
the interaction between SIPA1 and other molecules and the 
functions of SIPA1 in solid tumours.
2. Cloning and identification of the SIPA1 gene
The SIPA1 gene, also known as SPA1 (suppressor of 
phyA‑105),	was	first	cloned	in	1995	from	a	murine	lymphoid	
cell line, LFD 14, after IL‑2 stimulation (14). SIPA1 in mice 
was originally described as 3,518 bp long with a long open 
reading frame (ORF) (from position 1,199 to 3,280) and several 
short ORFs at the 5'‑end (14). In 1997, the same research team 
cloned the human SIPA1 cDNA from human peripheral blood 
lymphocytes (PBL) after stimulation with phytohemagglutinin 
and TPA (15). The human SIPA1 gene was mapped to chromo‑
some 11q13.1, spanning 12.8 kb. Human SIPA1 gene is highly 
homologous to the murine gene, containing 16 exons, amongst 
which exon 1, 91 bp of exon 2 (considered as 5'‑UTR) and the 
3'‑region 205 bp of exon 16 are untranslated (13). The human 
SIPA1 genome contains a much longer ORF of 1,042 residues 
(from position 297 to 3,425) (15). In the 5' terminal region of 
SIPA1 gene, residues from position 192 to 539 (containing part 
of the exon 5, exon 6, 7 and part of exon 8 in human) were found 
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to be highly homologous to human Rap1‑GAP (Gap related 
domain, GRD). Upstream of GRD there is a proline‑rich 
domain with the potential ability to bind SH3 and downstream 
of GRD there is the PDZ domain which consists of part of exon 
9. The 3' region, part of exon 14, exon 15 and translated part of 
exon 16 encode a leucine zipper (LZ)‑like domain, which was 
also found to be conserved in both humans and mice (13,15).
3. The structure and expression of SIPA1 protein
In mice, the SIPA1 gene encodes a 68 KDa protein (P68) 
with 693 amino acids, mostly located in the nuclei (14), whilst 
the human SIPA1 protein contains 1,042 amino acids with a 
molecular mass of 130 KDa (15). Three domains were identi‑
fied	in	the	SIPA1	protein:	i)	RapGTPase‑activating	protein	
(GAP) related domain (GRD) (350‑539); ii) PDZ domain 
(685‑759); iii) Leucine zipper like (LZ) domain (964‑1042) 
which is similar to myosin tail (13).
There is a proline‑rich domain including possible 
SH3‑binding motifs located in the N terminal to the GRD 
and upstream the LZ domain has a probable PEST sequence 
(Fig. 1) (15). Expression levels and localization of SIPA1 
protein vary in different human tissues and cells. SIPA1 
protein is most highly expressed in the lymphohematopoietic 
system such as spleen, bone marrow and thymus. SIPA1 may 
be located in the cytoskeleton, plasma membranes and nuclei 
depending on the type of cell and SIPA1's interaction with 
other proteins (13).
4. Germline polymorphisms in SIPA1
There are thousands of single‑nucleotide polymorphisms 
(SNPs) in the SIPA1 gene, of which seven SNPs located in 
the promoter or encoding regions of SIPA1 have been identi‑
fied	as	being	associated	with	tumourigenesis,	metastasis	and	
prognosis in previous studies (16‑20). Amongst them, most 
research has focused on three SNPs: i) rs931127, a G>A SNP 
located in the promoter region; ii) rs3741378, a C>T or C>G 
SNP which encodes for the replacement of a serine (Ser) to 
phenylalanine (Phe) amino acid in exon 3; iii) rs746429, a G>A 
SNP which encodes for a synonymous amino acid (Alanine, 
Ala) transformation in exon14.
These three SNPs are considered to be related to the 
development, metastasis and prognosis of breast, lung and 
cervical cancer (16‑25).
Other SNPs have been shown to be involved in breast 
cancer: rs2306364, a G>A SNP rs2448490, a G>A, G>C or 
G>T SNP, both of which encode for a synonymous amino 
acid (Alanine, Ala) transformation (16,19,25) In addition, 
rs75894763, a G>A SNP also encoding for a synonymous 
amino acid (Valine, Val) transformation (16) and rs75894763 
have been shown to be related to lung cancer (25). The G>T 
SNP, rs3741379, encoding for the replacement of an Ala to Ser 
amino acid has been reported to be involved in the process of 
lung cancer metastasis (25).
5. SIPA1 family and Rap1‑GTPase activating proteins
The initial function of SIPA1 was believed to be specific 
GAP activity for Ras‑related mediating proteins, Rap1, Rap2, 
Rsr1 and nuclear Ran (15), although recent research suggests 
that SIPA1 cannot work as a GAP for Ran or other small 
GTPases (15). SIPA1 overexpression induces rounding and 
eventual detachment of inherently adherent cells from the 
extracellular matrix by inhibiting endogenous Rap1 activation, 
indicating that Rap1 signals are involved in the regulation of 
cell adhesion and SIPA1 functions as a negative regulator of 
cell adhesion (14).
Human RapGTPase activating protein mainly consists of 
two subfamilies: i) SIPA1 family; ii) rapGAP family.
In addition to SIPA1, the SIPA1 family also includes 
SIPA1‑like1 (SIPAL1, also called E6TP1 or SPAR), SIPAL2, 
and SIPAL3; and the rapGAP family contains rapGAP1 
and rapGAP2 (13). All the RapGAPs share a homologous 
catalytic GRD domain in addition to an analogous PDZ 
domain (13,15).
6. SIPA1 interacting molecules
Nuclear SIPA1 and integrin β1. Nuclear SIPA1 has been shown 
to interact with a number of other proteins (Fig. 2) and activate 
the integrin β1 promoter in breast cancer cells (26). Nuclear 
SIPA1 has been shown to interact with and activate the integrin 
β1 promoter in breast cancer cells (26). After SIPA1 knock 
down in MDA‑MB‑231 cells, mRNA levels of SIPA1 were 
significantly	downregulated.	Chromatin	immunoprecipitation	
experiments revealed that nuclear SIPA1 could interact with 
the ITGB1 promoter and increase its transcription activity, 
causing phosphorylation changes in the integrin‑mediated 
FAK/Akt signalling pathway, thereby affecting the adhesion 
and invasion capability of cancer cells (26).
Association of SIPA1 and AF6. Co‑immunoprecipitation 
experiments demonstrated that SIPA1 bonded specifically 
with AF6 (afadin) in 293T cells transfected with both SIPA1 
and AF6. Further studies revealed that the binding occurred 
between the GRD domain of SIPA1 and the PDZ domain of 
AF6. AF6 was reported to localize at cell adhesion sites and 
have an association with the tight junction (TJ) protein ZO‑1 
(Zonula Occludens 1), SIPA1 also co‑localized with AF6 in 
similar cell to cell adhesion sites, so it was suggested that 
SIPA1 may also regulate TJs via AF6, although there is only 
scant evidence for this (27).
SIPA1 colocalizes with AQP2 in renal collecting ducts. 
Studies have shown that in renal collecting ducts, SIPA1 
directly binds to aquaporin‑2 (AQP2) and is involved in the 
regulation	of	trafficking	AQP2	to	the	apical	membrane.	AQP2	
has the ability to bind to molecules containing a PDZ domain, 
so SIPA1 with a PDZ domain can combine with AQP2 and 
play a role in the intracellular transport of AQP2. Studies also 
demonstrated that Rap1 signalling pathway was involved in 
the AQP2 intracellular transport system. As a regulation factor 
of Rap1, SIPA1 can control the transport process by inhibiting 
Rap1. Therefore the interaction between SIPA1 and AQP2 may 
be both direct and indirect (28).
Brd4 interacts with SIPA1. In HeLa cells, the bromodomain 
protein Brd4 was found to bind to the GRD domain of SIPA1 
directly and this interaction is mainly located in the cell 
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nucleus especially at or near the inner aspect of the nuclear 
membrane and enhanced the RapGTPase activity of SIPA1 for 
Rap1 and Rap2 (29,30). The combination of SIPA1 and Brd4 
promotes the cell cycle through M to G1 phases, which may 
also regulate cancer development (30).
SIPA1 is a metastasis efficiency modifier Mtes1. Genetic 
mapping	revealed	 thar	SIPA1	a	candidate	modifier	 for	 the	
Mtes1	(Metastasis	efficiency	suppressor	gene	1),	which	locates	
on the mouse chromosome 19 and contains a sequence of 
human's metastasis suppressor gene Brms1 (31). In mice, 
SIPA1 works as a candidate for underlying Mtes1. The mice 
kidney cancer cell line cos‑7 cells with the SIPA1 protein 
which had alanine (A) (SIPA1/741A) at the amino acid posi‑
tion 741 showed higher metastatic potential than those which 
had threonine (T) (SIPA1/741T) at the Position 741 in the PDZ 
domain (31). The higher metastatic potential could be induced 
through the mechanism that the Rap1GAP activating level 
was higher in the cells with SIPA1/741A SNP than those with 
SIPA1/741T SNP (31).
7. The multiple roles of SIPA1 in different cancer types
Breast cancer. Most research on the role of SIPA1 in 
cancer and cancer metastasis has focused on breast cancer. 
Immunohistochemical staining has shown that in breast cancer 
Figure 1. Structure of the human SIPA1 gene and protein. (A) Schematic representation of the SIPA1 gene structure. (B) The 16 exons of the SIPA1 gene. 
(C) Schematic representation of the SIPA1 protein structure. SIPA1, signal induced proliferation associated protein 1.
Figure 2. Schematic diagram presenting the interacting molecules of SIPA1. SIPA1 is central to the presented interactions. SIPA1 regulates the transcription of 
ITGB1 and controls proteins of the MMP family. Rap1 inhibition may modulate MMP via Akt signalling. AF6, presented in red, is the key molecule by which 
SIPA1 directly affects and adjusts tight junction proteins, maintaining cell‑to cell barrier function. SIPA1, signal induced proliferation associated protein 1; 
ITGB1, integrin β1 promoter; MMP, matrix metallopeptidase; AF6, afadin.
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patients, SIPA1 localized to the nuclear region. Its expression 
level may also be a predictive factor for lymph node metastatic 
status. Similarly, in breast cancer cell lines, SIPA1 is mainly 
localized to the nucleus in the aggressive breast cancer cell 
line MDA‑MB‑231 cells after transduction to overexpress 
SIPA1 (26). In vitro cell function experiments demonstrated 
that knockdown of SIPA1 reduced adhesion, migration and 
invasion in the MDA‑MB‑231 breast cancer cell line, but 
promoted the cells to proliferate (26). These changes may be 
due to the fact that nuclear SIPA1 interacts with and activates 
the integrin β1 promoter (ITGB1), thereby regulating the adhe‑
sion and invasion of breast cancer cells. Knockdown of SIPA1 
in the MDA‑MB‑231 cell line suppressed the integrin medi‑
ated FAK/Akt‑MMP9 signal pathway by markedly decreasing 
the phosphorylation levels of FAK and Akt and extracellular 
secretion of MMP9 (26). Thus the mechanism of SIPA1 
promoting breast cancer cell adhesion, invasion and metastasis 
may occur by regulating the integrin β1/FAK/Akt‑MMP9 
signalling pathway.
Prostate cancer. In patients with prostate cancer (CaP), high 
expression of SIPA1 was associated with poor prognosis and 
tumour metastasis (32). Similarly in the human CaP cell lines, 
LNCaP with low metastatic capacity inoculated in SCID 
mice was accompanied by undetectable levels of SIPA1, 
while PC3 cells with high metastatic capacity in SCID mice 
was accompanied by high levels of SIPA1 expression (32). 
After transduction of SIPA1, the low metastatic LNCaP cells 
inoculated into the testis of SCID mice exhibited a propensity 
to metastasize to the abdominal lymph nodes. Following 
knockdown of SIPA1, the highly metastatic PC3 cells exhibited 
reduced metastatic potential and there was no significant 
change in the size of primary tumour in both groups (32). 
Thus the effect of SIPA1 on prostate metastasis is greater 
than the effect on proliferation. In vitro, after transduction 
of SIPA1 in LNCaP cells, expression of SIPA1 resulted in 
decreased adhesion of CaP cells to the extracellular matrix 
(ECM). Nuclear Brd4 and ECM‑related gene expression were 
down‑regulated, which was regulated by Rap1 activation (32). 
A meta‑analysis of human gene expression data (Oncomine 
website: https://www.oncomine.org/resource/login.html) 
from prostate, lung and a variety of solid tumours showed 
overexpression of SIPA1 in human primary prostate cancer 
tissues which was related to cancer metastasis progress.
Oral squamous cell carcinoma. Expression of SIPA1 in both 
human oral squamous cell carcinoma (OSCC) and OSCC 
cells is higher than in normal tissue, and is related to regional 
lymph node metastasis in OSCC patients. In the OSCC cell 
line HSC‑3 and HSC‑4, the knockdown of SIPA1 reduced the 
ability of cells to invade and migrate, but increased the adhe‑
sion	of	cells	and	had	no	significant	effect	on	proliferation	
compared with the control group. In the same cell line, knock‑
down of SIPA1 down‑regulated the cytosolic expression of 
BRD4, but abundant BRD4 protein was still expressed in the 
nucleus (33). The interaction between SIPA1 and BRD4 may 
promote OSCC metastasis. Expression of ITGB1, an integrin 
which is known to be an important marker in cell invasion 
and	adhesion,	was	significantly	higher	in	SIPA1	knock	down	
cells than control cells. However, expression of MMP7 
(membrane metalloproteinase 7) which has an essential role 
in tumour invasion, growth and metastasis, was markedly 
reduced after knockdown of SIPA1 (33). Therefore, SIPA1 
and its interaction with BRD4 may impact the development 
and metastatic progression of OSCCs by regulating ITGB1 
and MMP7.
Colorectal cancer. In human colorectal adenocarcinoma 
patients, there was increased expression of SIPA1 in tumours, 
especially in well‑differentiated and moderately differentiated 
tumours compared to poorly differentiated tumours. Patients 
with a higher expression level of SIPA1 had a poor prognosis. 
In vitro experiments demonstrated that after knockdown of 
SIPA1 in HT115 and Caco‑2 colorectal cancer cell lines, the 
potential of cancer cells to invade, adhere and migrate was 
increased compared to the control group, while the ability to 
proliferate was decreased (34). This suggests that SIPA1 may 
have an active role during progression of colorectal adenocar‑
cinoma.
Cervical cancer. Two SNPs in SIPA1 (rs931127, 313G>A and 
rs746429, 2760G>A) are potentially related to an increased 
risk of nodal metastasis in cervical cancer. The G allele at both 
rs931127 and rs746429 in SIPA1 was associated with nodal 
disease in cases and controls. In terms of tumour size, patients 
with smaller stage IB1 tumours having the G allele showed an 
increased risk of nodal metastases at SIPA1 rs746429 and at 
rs931127, but the correlated trend between polymorphisms in 
SIPA1	and	nodal	metastasis	were	not	significant	in	Stage	IB2	
tumours (which are larger lesions). The G allele in SIPA1 at 
both	rs746429	and	rs931127	was	significantly	related	to	nodal	
disease in patients without lymphovascular invasion (LVI), 
which was considered as an independent poor prognostic 
factor in cervical cancer patients. The GG genotype was asso‑
ciated with a markedly higher risk of nodal disease in both 
SNPs of SIPA1 in patients without LVI. Histologically, SNPs 
in SIPA1 rs746429 and rs931127 were not related to histology 
types (adenocarcinoma or squamous cancer). Moreover, SNPs 
of SIPA1 made no difference in the overall survival of cervical 
cancer patients (20).
Lung cancer. Previous studies have focused on the polymor‑
phism of SIPA1 in lung cancer development and metastasis. 
Three SNPs were found to be involved in lung cancer, 
rs931127 A>G, rs2448490 G>A and rs3741379 G>T (24,25). 
In a southern Chinese population, a high frequency of the G 
allele	at	rs931127	was	significantly	correlated	with	the	risk	of	
lung	cancer,	but	no	significant	connection	was	observed	for	
the other two SNPs. From the perspective of tumour staging 
and grading, the fusion of the G allele in rs931127 was also 
associated with worse clinical stage, nodal metastasis and 
distal metastasis. The SNP rs931127 A>G in the promoter of 
SIPA1 was highly associated with tumourogenesis and metas‑
tasis of lung cancer (25). Another study suggested that G allele 
fusion	in	SNP	rs931127	A>G	was	significantly	correlated	with	
more serious progression free survival (PFS) in the patients 
with non‑small cell lung cancer (NSCLC) (24). Therefore the 
SIPA1	SNP	rs931127	A>G	may	be	identified	as	an	indepen‑
dent prognostic predictive factor for progression free survival 
(PFS) in NSCLC patients (24,25).
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Gastric cancer. There has been little previous research 
regarding the role of SIPA1 in gastric cancer. A single study 
demonstrated both mRNA level (detect by qPCR) and protein 
expression (detected by western blotting) of SIPA1 in gastric 
tumour tissues was lower than in adjacent normal tissues. 
However, on the contrary, IHC that positive staining of SIPA1 
was	significantly	higher	in	gastric	cancer	tissue	than	in	adjacent	
normal tissue (35). Positive staining of SIPA1 in the tumour 
from gastric cancer patients was markedly associated with the 
degree of differentiation, lymph node metastases and clinical 
grading (35). The expression and function of SIPA1 in gastric 
cancer and its mechanisms of action need to be further explored.
Melanoma. Limited research regarding the role of SIPA1 in 
melanoma has been conducted. One study indicated that in 
fast‑growing	melanoma	there	was	significant	overexpression	
of SIPA1, resulting in the inactivation of Rap1 and aggressive 
melanoma cell models. When knockdown down of SIPA1 in 
these melanoma models was carried out, adhesion capability 
was enhanced but clonogenic potential and migration ability 
were reduced (36). These data suggest that SIPA1 interacts 
with Rap1 and may have a complex role in the regulation of 
melanoma development and metastasis.
8. Conclusion
Although it has been nearly 30 years since the discovery of 
SIPA1, there has been a scarcity of research as regards the role 
of SIPA1 in cancer development or prognosis. In almost all 
types of cancers studied, SIPA1 was associated with lymph node 
metastasis, which suggests that SIPA1 might be a marker of, or 
at least associated with, cancer development and hence patients' 
prognosis. Whether it could prove to be a reliable biomarker for 
prognosis remains to be seen and further work is necessary.
Numerous studies have demonstrated that interactions 
between SIPA1 and several other molecules, known to be 
involved in control of cell growth and division, could offer 
a potential model for studying the process of cancer metas‑
tasis. In relation to this, the role of SIPA1 in Rap1 signalling 
pathway may also shed light on the regulation of this pathway 
in metastatic disease and provide a novel target in the future.
We can conclude that SIPA1 may be a new target for cancer 
therapy in those patients with tumours which have resistance to 
current chemotherapy agents. But so far there were no ongoing 
or potential clinical trials for targeting SIPA1. Potential inhibi‑
tors to SIPA1 could have a direct bearing on its putative role 
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